‘Hunker Down, Expect The Worst And Hope For The Best’: Investment Analyst Advises Medtech Businesses To Cut Costs
Executive Summary
Maxim Jacobs, managing partner at Edison Investment Research, urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.
You may also be interested in...
Wall Street Tries To Guess The Impact Of Pandemic On Medtech Revenues
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.